BACKGROUND INFORMATION ON THE PROCEDURE 
1.1 
Submission of the dossier 
The  applicant  Roche  Registration  Ltd.  submitted  on  25  April  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  MIRCERA,  through  the  centralised 
procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The 
eligibility  to  the  centralised  procedure  was  agreed  upon  by  the  EMEA/CHMP  on  13  October  2005
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application. 
The  application  submitted  is  a  complete  dossier  composed  of  administrative  information,  complete 
quality data, non-clinical and clinical data based on applicants’ own tests and studies and bibliographic 
literature substituting and supporting certain tests or studies. 
Scientific Advice 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur:   Gonzalo Calvo Rojas 
Co-Rapporteur:  
Pekka Kurki 
1.2 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 25 April 2006. 
The procedure started on 24 May 2006.  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 11 August 
2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
17 August 2006.  
The BWP adopted a final report on 13 September 2006 to be included in the List of questions. 
A clarification meeting with the Rapporteurs on the List of Questions was held on 19 September 
2006. 
During  the  meeting  on  18-21  September  2006  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 21 September 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
8 January 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 22 February 2007. 
The BWP adopted a further final report on 14 March 2007. 
A clarification meeting with Rapporteurs on the list of outstanding issues was held on 21 March 
2007. 
During  the  CHMP  meeting  on  19-22  March  2007  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing and in an oral explanation by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues to be addressed in 
writing on 12 April 2007. 
The Rapporteurs circulated an updated Joint Assessment Report on the applicant’s responses to 
the list of outstanding issues to all CHMP members on 7 May 2007. 
A clarification teleconference with the Rapporteurs took place on 10 May 2007. 
The  BWP  adopted  a  further  final  report  on  16  May  2007  after  an  oral  explanation  by  the 
applicant before the BWP on 14 May 2007. 
©EMEA 2007 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
• 
The  outstanding  issues  were  addressed  in  a  written  response  submitted  by  the  applicant  on  
16 May 2007. 
During  the  meeting  on  21-24  May  2007  the  CHMP, in  the light  of  the  overall data  submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  MIRCERA  on  24  May  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 23 May 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 20 July 2007. 
©EMEA 2007 
2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
